Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Editas Medicine, Inc. Director's Dealing 2017

Aug 21, 2017

33260_dirs_2017-08-21_cf3c2d95-5540-452e-87e7-1f4db3318665.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2017-08-17

Reporting Person: Cole Douglas G. (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-08-17 Common Stock J 1686 Acquired 3171 Direct

Footnotes

F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,361,400 shares and 340,349 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 57,022 shares and 11 shares it received from Flagship IV and Flagship IV-Rx, respectively. Mr. Cole, a member of Flagship IV LLC, received 1,686 shares through such distribution.